Two genetic mutations tied to early-onset Parkinson's disease cause the alpha-synuclein protein to form brain-damaging fibrils faster than the normal version.
2 mutations, both faster fibril formationBoth A53T and A30P alpha-synuclein mutations formed Lewy body-like fibrils more rapidly than wild-type protein in vitro
What the researchers found
Both mutant forms of alpha-synuclein (A53T and A30P), which are linked to early-onset Parkinson's disease, form Lewy body-like fibrils more rapidly than the wild-type protein in test-tube conditions. The A53T mutation produced fibrils fastest. All three forms of alpha-synuclein were disordered at low concentrations, but at higher concentrations they assembled into fibrils and spherical structures characteristic of the brain inclusions seen in Parkinson's patients.
Why it matters
This was one of the first studies to directly show that genetic mutations linked to familial Parkinson's disease accelerate the physical clumping of alpha-synuclein into the fibrous deposits found in affected brain cells. It provided a mechanistic bridge between genetics and pathology, suggesting that speeding up protein aggregation may be how these mutations cause earlier disease onset.
How the study worked
in-vitro protein folding and aggregation assays with recombinant wild-type and mutant alpha-synuclein; circular dichroism spectroscopy, atomic force microscopy, and electron microscopy
Who was studied
Recombinant human alpha-synuclein protein (wild-type, A53T mutant, A30P mutant)
What this study cannot tell us
In vitro study using purified recombinant protein — does not account for the complex cellular environment, other Lewy body components, or in vivo conditions. No quantitative kinetic rate constants reported. Limited to two known familial mutations.
How to read the evidence
This is an early-stage in vitro study using purified recombinant proteins in a test tube. While published in the high-impact journal Nature Medicine and foundational for the field, it does not involve cells, animals, or human subjects.
When this study was published
Published in 1998, this is a foundational study in Parkinson's research. Its core finding — that familial mutations accelerate alpha-synuclein aggregation — has been extensively validated and remains central to current understanding of the disease.
The bigger picture
This landmark study helped establish the 'aggregation hypothesis' of Parkinson's disease — the idea that the disease progresses because alpha-synuclein misfolds and clumps together. It opened the door to decades of research into therapies that might slow or prevent this aggregation, including peptide-based inhibitors designed to block fibril formation.
Questions still open
- Can small molecules or peptides be designed to slow alpha-synuclein aggregation and delay Parkinson's onset?
- How does the cellular environment inside neurons modify the fibril formation rates seen in this test-tube study?
- Do other undiscovered alpha-synuclein mutations also accelerate aggregation in sporadic Parkinson's cases?
Common questions
What is alpha-synuclein and why does it matter in Parkinson's disease?
Does this study mean all Parkinson's disease is caused by alpha-synuclein clumping?
Read the original research
Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
Nature medicine, 4(11), 1318-20
Citation
Conway, K A; Harper, J D; Lansbury, P T. (1998). Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.. Nature medicine, 4(11), 1318-20.